Hanbury FZE
  • Search
  • Home
  • Products & Services
    • Nutraceutical Ingredients
      • Standardized Phyto Extracts
      • Beverage/Liquid Dietary Supplements
      • GRAS Affirmed Ingredients
      • Minerals for Nutritional Use
      • Phytochemicals for Nutritional Use
      • Multi-enzyme Blends
      • Natural Protein
      • Nutritional Fine Chemicals
      • Phyto Functional Blends
      • Geroceuticals™
      • Prebiotics, Probiotics, Postbiotics and Synbiotics
      • Super Critical Fluid (SCF) Extracts
      • Specialty Fine Chemicals
    • Cosmeceutical Ingredients
      • Natural Actives
      • Peptides
      • Anti-Glycation
      • Dermaceuticals
      • Nutricosmetics
      • Probiotics & Postbiotics
      • Proprietary Cosmeceutical Blends
      • Speciality Chemicals
    • Services
      • Custom Manufacturing
      • Contract Manufacturing
      • Product Specification Sheet
    • Pharma
      • Natural Drugs
      • Chiral Drug Intermediates
  • About Us
    • Our Story
    • Our People
    • Research & Development
    • Manufacturing Facilities
    • Intellectual Properties
  • Newsroom
    • Press Release
    • FAQs
      • BioPerine®
      • Citrin®K
      • Cococin™
      • Curcumin C3 Complex®
      • Curcumin C3 Reduct®
      • ForsLean®
      • GarCitrin®
      • LactoSpore®
      • LeanGard®
  • Contact Us

Home / Sabinsa’s Curcumin C3 Complex® with BioPerine® shows protective role in lipid profile modification in type 2 diabetes in published study

Sabinsa’s Curcumin C3 Complex® with BioPerine® shows protective role in lipid profile modification in type 2 diabetes in published study

Sabinsa’s Curcumin C3 Complex® with BioPerine® shows protective role in lipid profile modification in type 2 diabetes in published study

First Evidence of Lp(a) Reduction

A pivotal study that further consolidates the ameliorating role that Sabinsa’s C3 Complex®/BioPerine® combination plays in the context of diabetes has just been published in Complementary Therapies in Medicine Panahi et al 33(2017)1-5  http://dx.doi.org/10.1016/j.ctim.2017.05.006. The study demonstrated the protective role the C3 Complex®/BioPerine® combo play in maintaining HDL functionality, reducing non-HDL-C and for the first time in curcumin research, improvements in Lp(a) [Lipoprotein(a)], a structural component of LDL.

The results of a 12-week randomized double-blind placebo-controlled trial on subjects with type-2 diabetes showed promising outcome of using a combination of Sabinsa’s proprietary branded ingredients Curcumin C3 Complex® (1000mg/day) and BioPerine® (10mg/day). Fifty subjects in the active group and an equivalent number in the placebo group successfully completed the trial. The analysis of the results showed that the Curcumin C3 Complex®/BioPerine® combination reduced the atherogenic lipid indices including non-HDL-cholesterol and Lp(a) while showing an increase in HDL-levels and improving HDL-functionality.

While the importance of lowering non-HDL-cholesterol fraction has long been recognized, nutritional intervention to reduce Lp(a), a protective armor of the bad cholesterol LDL, has never been demonstrated in a clinical trial for curcuminoids. The absence of effective drug therapy to reduce Lp(a), especially in diabetic patients who are more prone to cardiac events, further accentuates the importance of C3 Complex®/BioPerine® combo in such a scenario.

The only drug intervention to reduce Lp(a) is the recently introduced PCSK9 inhibitors that are extremely expensive and available only as an injectable. Lp(a) has been recognized as an independent risk factor for atherosclerosis, hence a nutritional intervention to reduce Lp(a) is immensely welcome.

“The overall conclusions in this study together with earlier studies on C3 Complex® / BioPerine® combination add to the body of science on its positive role in the health maintenance of diabetic subjects,” said Sabinsa founder Dr. Muhammed Majeed, who contributed to the published study

Back
top

HEADQUARTERS

Hanbury FZE


Jebel Ali Free Zone


Warehouse No. RA08AB05


P O Box. 61091


Dubai


United Arab Emirates


+971 4 883 8981

+971 4 883 8978

mail@hanburyfze.ae

CERTIFICATES

Certificate Logos Certificate Logos Certificate LogosCertificate Logos

Global Offices

USA India
Utah, USA Japan
Australia Poland
Brasil Korea
Canada South Africa
China Vietnam
Germany  

CONTACT US

    © 2023 Hanbury FZE. All Rights Reserved | Powered by Edkal Technologies | Privacy Policy | Terms of Use | Sitemap | Disclaimer

    • Facebook
    • Twitter
    • LinkedIn
    Disclaimer

    US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

    EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.